Evidence map›Paper›PMID 40524025›Full record

ReviewPharmaceutical research2025

The Next Frontier: Unveiling Novel Approaches for Combating Multidrug-Resistant Bacteria.

Praveen Mallari, Leila D Rostami, Ida Alanko, Fadak Howaili, Meixin Ran, Kuldeep K Bansal, Jessica M Rosenholm, Outi M H Salo-Ahen

Abstract readReview
In one paragraph

Review in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Combined use of methyl gallate and N-acyl homoserine lactonase YtnP to inhibit biofilm formation in Burkholderia thailandensis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Praveen MallariDepartment of Zoology, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, 484887, India. mallaripraveen950@gmail.com.
Leila D RostamiPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Pharmacy, Åbo Akademi University, 20520, Turku, Finland.
Ida AlankoPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Pharmacy, Åbo Akademi University, 20520, Turku, Finland.
Fadak HowailiPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Pharmacy, Åbo Akademi University, 20520, Turku, Finland.
Meixin RanPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Pharmacy, Åbo Akademi University, 20520, Turku, Finland.
Kuldeep K BansalPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Pharmacy, Åbo Akademi University, 20520, Turku, Finland.
Jessica M RosenholmPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Pharmacy, Åbo Akademi University, 20520, Turku, Finland.
Outi M H Salo-AhenPharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Pharmacy, Åbo Akademi University, 20520, Turku, Finland. outi.salo-ahen@abo.fi.ORCID http://orcid.org/0000-0003-0725-126X

Funding

Svenska Kulturfonden 188147Svenska Kulturfonden 190913
6 · The paper itself

Abstract

backgroundThe rapid occurrence of bacterial antibiotic resistance poses a significant threat to public health worldwide. Since particularly multidrug-resistant (MDR) pathogens are becoming untreatable with currently available antibiotics, new treatment modalities must be deployed.

objectivesThis review explores the recent advancements and the enduring challenges in new antibacterial development for drug-resistant organisms.

resultsWe describe how bacterial resistance to antibiotics arises and discuss why the traditional drug discovery routes are inefficient. The best alternative strategies to overcome these challenges might include exploring new bacterial pathways, utilizing compounds with antibacterial activities from the human microbiome, and repurposing existing drugs. Moreover, novel drug delivery mechanisms that leverage, for example, nanotechnology-based carriers may be breakthrough ideas that can increase antibiotic efficacy and, at the same time, reduce toxicity. Current clinical trials of next-generation drugs indicate that some treatments possess excellent potential to overcome the MDR issue.

conclusionDespite the substantial obstacles to getting bench findings to the patient, numerous scientists are still working towards this goal. Both the application of antibiotic stewardship principles and timely considerations through the regulatory pathways are needed to release the next generation of antibiotics that are suitable for the fight against superbugs.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsDrug Resistance, Multiple, BacterialAnimalsDrug Delivery SystemsDrug DiscoveryDrug RepositioningHumansAnti-Bacterial AgentsAlternative drug discovery strategiesAntibacterial developmentAntibiotic resistanceNext-generation antibioticsNovel drug delivery mechanisms

Identifiers

PMID40524025
PMCPMC12222395

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.